Literature DB >> 24625917

Plasma homocysteine in Alzheimer's disease with or without co-morbid depressive symptoms.

Eva Kitzlerová1, Zdenĕk Fisar1, Roman Jirák1, Martina Zvĕrová1, Jana Hroudová1, Hana Benaková2, Jirí Raboch1.   

Abstract

OBJECTIVE: Elevated homocysteine is associated with a variety of diseases, including Alzheimer's disease (AD) and depressive disorder. This study was designed to detect an association between plasma homocysteine and AD with or without co-morbid depressive symptoms.
METHODS: Plasma homocysteine concentrations were measured in 85 AD patients (36 of them with depressive symptoms), 33 non-AD patients with a depression diagnosis and 44 healthy controls, all aged above 50 years.
RESULTS: Positive correlation between age and homocysteine was confirmed. Significantly higher mean plasma homocysteine was found in AD patients, but not in depressive patients, when compared with controls. We confirmed significant correlation between homocysteine concentration and the degree of cognitive impairment in AD patients. There was no incremental effect of concurrent depressive symptoms on homocysteine concentration in AD patients.
CONCLUSION: The association of high homocysteine with degree of cognitive impairment or stage of dementia in AD indicate potential role of high plasma homocysteine as a biomarker of the disease and/or indicator of brain damage during the progression of AD dementia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24625917

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  6 in total

Review 1.  Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?

Authors:  Xin Du; Terence Y Pang
Journal:  Front Psychiatry       Date:  2015-03-09       Impact factor: 4.157

2.  MTRR rs326119 polymorphism is associated with plasma concentrations of homocysteine and cobalamin, but not with congenital heart disease or coronary atherosclerosis in Brazilian patients.

Authors:  Melanie Horita; Carolina Tosin Bueno; Andrea R Horimoto; Pedro A Lemos; Antonio A Morandini-Filho; Jose E Krieger; Paulo C J L Santos; Alexandre C Pereira
Journal:  Int J Cardiol Heart Vasc       Date:  2016-11-24

3.  Interactions Among Polymorphisms of Susceptibility Loci for Alzheimer's Disease or Depressive Disorder.

Authors:  Eva Kitzlerová; Zdeněk Fišar; Petra Lelková; Roman Jirák; Martina Zvěřová; Jana Hroudová; Ada Manukyan; Pavel Martásek; Jiří Raboch
Journal:  Med Sci Monit       Date:  2018-04-28

4.  Emodin Rescued Hyperhomocysteinemia-Induced Dementia and Alzheimer's Disease-Like Features in Rats.

Authors:  Peng Zeng; Yan Shi; Xiao-Ming Wang; Li Lin; Yan-Jun Du; Na Tang; Qun Wang; Ying-Yan Fang; Jian-Zhi Wang; Xin-Wen Zhou; Youming Lu; Qing Tian
Journal:  Int J Neuropsychopharmacol       Date:  2019-01-01       Impact factor: 5.176

5.  MiR-483-3p improves learning and memory abilities via XPO1 in Alzheimer's disease.

Authors:  Gang Luo; Xiaoyan Wang; Changya Liu
Journal:  Brain Behav       Date:  2022-07-14       Impact factor: 3.405

6.  One-Carbon Metabolism in Alzheimer's Disease and Parkinson's Disease Brain Tissue.

Authors:  Karel Kalecký; Paula Ashcraft; Teodoro Bottiglieri
Journal:  Nutrients       Date:  2022-01-29       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.